Company overview
Basic information
Company name
Druskininkų gelmė, UAB
Company code
252041370
Registered address
Prienų r. sav., Jieznas, Mokyklos g. 13, LT-59427
Registration date
1992-09-23
Company age: 34 y. 1 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Travel agency activities
Ownership form
Private without foreign capital
Uždaroji akcinė bendrovė "Druskininkų gelmė"
Company code: 252041370
Address: Prienų r. sav., Jieznas, Mokyklos g. 13, LT-59427
Description
This description was generated by artificial intelligence.
Druskininku gelme, UAB (company code 252041370) is an operational private limited liability company registered in 1992. It is classified as a private company within the national private non-financial sector and is described as privately owned, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and with foreign investor capital included. The company has CEO-only governance and is classified as micro-sized. Its activity under EVRK code O.79.11.00 is travel agency activities. The registered address is Mokyklos g. 13, Jieznas, Prienu r. sav., Kauno apskr. Financially, the company reported revenue of €38.9K in 2025, slightly above 2024, and net profit of €3.1K with an 8.0% profit margin. Revenue remains below the 2023 level, but the 2025 result was substantially stronger than 2024. Equity stood at €14.0K at the end of 2025, with liabilities of €347. The staff base has been small: the company averaged 3 employees in 2025 and so far in 2026 averages 1 employee. Average monthly wage increased from €420.18 in 2023 to €470.00 in 2024 and €530.17 in 2025.
Download a detailed company report
Make confident decisions with all the information about Druskininkų gelmė, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.